Cardinal Health is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for healthcare facilities. Our Nuclear & Precision Health Solutions business has more than 40 years of experience and insight in the radiopharmaceuticals industry, operating the largest national network of more than 130 nuclear pharmacies and more than 30 PET sites and other manufacturing facilities, including the only commercial Alpha contract manufacturing site in the United States and our Center for Theranostics Advancement.
Radiopharm Theranostics is a clinical-stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. The company has a pipeline of four distinct and highly differentiated platform technologies spanning peptides, small molecules, and monoclonal antibodies for use in cancer, in pre-clinical and clinical stages of development from some of the world’s leading universities and institutes. The pipeline has been built based on the potential to be First to Market or Best in Class. The clinical program includes five Phase 2 and two Phase 1 trials in a variety of solid tumor cancers including breast, kidney and brain, with a total of 133 patients dosed to date. To realise this potential, Radiopharm has formed a world class management team recruited from some of the most prestigious radiopharmaceutical companies and universities globally. The CEO Riccardo Canevari, was until recently, the Chief Commercial Officer at Novartis’ Advanced Accelerator Applications one of the world’s leading radiopharmaceutical companies, and the Chief Medical Officer, Professor David Mozley, was until recently, Professor of Nuclear Medicine at the prestigious Cornell University in New York. The board comprises experienced and seasoned life science-focused Directors with prior radiopharmaceutical and biotech experience.
Oncodesign is a biopharmaceutical company dedicated to precision medicine. With its unique experience acquired by working with more than 800 clients along with its comprehensive technological platform combining state-of-the-art medicinal chemistry, pharmacology, bioanalysis, pharmaco-imaging & artificial intelligence, Oncodesign orients, drives & executes the development of drug candidates from hit findings up to early clinical phases. Oncodesign has specialties in imaging and targeted radiotherapies.
Our expertise & capacities enable to provide imaging solutions to monitor your drug in order to better predict its efficacy. Our multimodal imaging platforms are an open door for non-invasive techniques to understand the pharmacology of your compound in less than 6 months. Finally, we have a unique offering dedicated to pre-clinical evaluation of TRT: a unique combination of our skills in radiochemistry and in vivo pharmaco-imaging in order to assess systemic radiotherapy efficacy.
ABX-CRO is an independent international CRO with more than 20 years of experience in radiooncology, dosimetry, and molecular radiotherapy. ABX-CRO offers product development services from non-clinical through Phase-0 microdosing to global Phase III studies. Highly specialised radiooncology trials require close multidisciplinary interaction of pharmacists, physicists, clinicians and statisticians, as well as clinical trial experts all the way through from study design and conduct to final statistical analysis. Reflecting this, ABX-CRO comprehensively integrates scientific, medical and clinical trial management expertise required for advanced imaging and therapeutic trials. We closely cooperate with key opinion leaders, research institutes and universities worldwide to realise non-clinical studies for novel IMPs and to ensure recruitment and adequate treatment facilities for a wide range of indications.
IBA RadioPharma Solutions & SCK CEN
IBA RadioPharma Solutions
Based on 35 years of experience, IBA RadioPharma Solutions helps nuclear medicine department to design, build and operate PET centers for the production of radiopharmaceuticals used for the detection and treatment of cancer and other critical diseases.
SCK CEN (Belgian Nuclear Research Center)
SCK CEN (Belgian Nuclear Research Center) is a global leader in the field of nuclear research, services and education for 70 years now. As a preclinical research partner and manufacturer of high-quality medical radioisotopes, SCK CEN is dedicated to help partners enhance the life-saving potential of their molecules. Engage our unique expertise, infrastructure and licenses to handle a variety of isotopes to discover new opportunities in the fight against cancer.
Located near Aix-en-Provence, in France, PMB is a 160-employee SMB. With a strong expertise in brazing, the company designs and manufactures complex mechanical assemblies and components (ceramic-metal, radio-frequency…), linear particle accelerators and cyclotrons. PMB is part of the French industrial group ALCEN.
PMB has developed a cutting-edge, automated radiopharmaceutical production system for PET imaging, combining a cyclotron with a robotized radiochemistry room. Our GMP-compliant R&D iMiLAB synthesizer allows the development of various radiopharmaceuticals using microfluidic cassettes. It can also be used for the production of single doses or small batches.
FIELD-LAB - NRG
MILabs provides high-performance stand-alone and integrated SPECT, PET, CT and, Optical Imaging systems for molecular imaging and in vivo imaging research. Our multimodal imaging technology, each with 2D, 3D, and 4D imaging capabilities, enables researchers to improve diagnostics and therapy development through complementary, data-rich, co-registered images. Each modality by itself gives data beyond the capabilities of any other stand-alone system.. Through continuous innovation and supportive service, the team at MILabs is dedicated to ‘providing small details for big discoveries’ for a wide range of imaging research programs. MILabs systems contribute significantly to developing new diagnostic solutions and therapies for diseases such as diabetes, cancer, cardiac and neurodegenerative diseases.
IONETIX is a US-based cyclotron technology company founded in 2009 as an end-to-end radiopharmaceutical solution provider. As a leading manufacturer of diagnostic radionuclide imaging agents, IONETIX is now applying their cyclotron technology and expertise on Targeted Alpha Therapy focusing on isotope production, drug manufacturing and distribution of alpha radionuclides, including Ac-225 and At-211.
Minerva Imaging is a scientifically-driven CRO focussed on targeted radionuclide therapy with the use of advanced oncology models and molecular imaging for translational cancer research and drug development.
With over 10 years of experience in targeted radionuclide therapy, we are experts in designing and performing preclinical targeted radionuclide therapy studies. We operate a facility with on-site radiochemistry and vivarium for small and large animals equipped with molecular imaging systems. We are licensed to work with relevant isotopes for targeted radionuclide therapy and diagnostics.
We engage with our clients to understand their scientific questions and discuss how our methods and capabilities can provide answers. Our competences build on more than two decades of research within oncology, targeted radionuclide therapy and molecular imaging performed at the University of Copenhagen and Rigshospitalet, the National University Hospital of Denmark.
Curium is the world’s largest nuclear medicine company with more than a century of industry experience. We develop, manufacture and distribute world-class radiopharmaceutical products to help patients around the globe. Our proven heritage combined with a pioneering approach are the hallmarks to deliver innovation, excellence and unparalleled service.
With manufacturing facilities across Europe and the United States, Curium delivers SPECT, PET and therapeutic radiopharmaceutical solutions for life-threatening diseases to over 14 million patients annually. The name ‘Curium’ honors the legacy of pioneering radioactive researchers Marie and Pierre Curie, after whom the radioactive element curium was named and emphasizes our focus on nuclear medicine. The tagline ‘Life Forward’ represents our commitment to securing a brighter future for all those we serve: An enhanced quality of care for our patients. A trusted partner to our customers. A supportive employer to our valued team.
Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical, and medical device industries. We have proven expertise in radiation oncology, radiation device, and radiopharmaceutical clinical trials. Our radiation group has a consistent track record of success as a full-service CRO that can ensure flexibility to adapt to the unique needs of each radiation clinical trial. Our in-house experts are board-certified radiation oncologists, radiologists, radiation physicists, and dosimetrists and are fully involved throughout each study and provide leadership for Sponsors. Consistent oversight by medical monitors and physicists coupled with early planning and collaboration ensures that our sponsor’s trials are executed to their specifications throughout the life cycle of the study.
NorthStar Medical Radioisotopes is a commercial-stage nuclear medicine company that manufactures and distributes diagnostic and therapeutic radiopharmaceuticals. The Company’s proprietary state-of-the-art technology and proven management team have propelled it to the forefront of U.S. medical radioisotope production as the sole domestic producer of the diagnostic imaging radioisotope molybdenum-99 (Mo-99). Mo-99 is used to generate technetium-99m (Tc-99m), the standard of care in diagnostic imaging to assess the extent and severity of heart disease and cancer. NorthStar’s unique Mo-99 production process is non-uranium-based and environmentally friendly. NorthStar is expanding its industry-leading position in the emerging area of therapeutic radioisotopes, which are used in targeted radiopharmaceutical therapy to treat cancer, respiratory and other diseases. Using first-in-kind and environmentally-sound electron accelerator technology, NorthStar is poised to be the first commercial-scale producer of therapeutic radioisotopes actinium-225 (Ac-225) and copper-67 (Cu-67).
Eczacıbaşı-Monrol is an innovative, international supplier of radiopharmaceuticals for diagnosis and treatment in nuclear medicine. The company exports to more than 50 countries around the globe and has manufacturing sites and operational projects in different regions. Monrol has entered the theranostic market in 2019 as one of the few producers of CA Lutetium-177 worldwide, and have ensured the uninterrupted supply of this critical product to patients in 10 countries over the past three years. Also its new product’s, NCA Lu-177 which is compliant with European Pharmacopeia, FDA registry of the DMF opens the door for its use in US clinical trials.
Now, to support its growth in theranostic field, it’s establishing a new GMP certified facility exclusive for theranostic R&D and production, and its inhouse invented device will enable it to supply its Lutetium with maximum capacity. Eczacıbaşı-Monrol is headquartered in Istanbul and delivers high quality, customer-oriented service to nuclear medicine centres through more than 30 distributors.
Chelatec was founded in 2000 by seasoned scientists trained in the development of radiopharmaceuticals. Experts in the use of radioactive tracers, they decided to offer their knowledge in preclinical development of targeted radiotherapeutics to pharma and biotech.
With state-of-the-art fully equipped laboratories for radiolabeling, radioanalyses, handling of cells and housing of animals, Chelatec is recognized for its reliable expertise and offers a unique combination of custom radiolabeling, in vitro assays and in vivo investigations capabilities.
Specializing in radiopharmaceutical R&D, Chelatec will provide you with information on your Investigational Medicinal Product to be part of the documentation package. All quality and non-clinical safety data required for translation of a radiopharmaceutical.
Our services cover/include:
- Radioactive labeling
- Analytical controls (HPLC, iTLC/TLC, SDS-PAGE...)
- Stability studies (storage stability, plasma stability)
- In vitro assays
(Binding affinity, IRF, internalization, cytotoxicity, autoradiography on tissue sections)
- In vivo investigations
(Pharmacokinetics, biodistribution, efficacy, preclinical dosimetry)
Founded in 2005 as a spin-off of the Institut de Chimie Moléculaire de l’Univerisité de Bourgogne, CheMatech is a unique company in Europe specialized in the design and production of chelators (DOTA, NOTA derivtaives) for Nuclear Medicine and Molecular Imaging. These molecules are used for the radiolabeling of biovectors such as peptides or antibodies. CheMatech provides its clients with a catalog of chelators suitable for most radiometals used for PET, SPECT or therapy and also offers custom syntheses, from the design of the chelator to the production in bulk. CheMatech is able to produce GMP chelators, and related molecules, for the production of APIs from gram to kilogram scale. CheMatech constantly innovates and offers new solutions thanks to internal R&D activity and joint research programs with internationally recognized research teams.
Based in Dijon, France, CheMatech’s facilities include 500 m2 of laboratories with a separate GMP area. With 1300 clients all over the world, the company is present in more than 30 countries.
Trasis was founded in 2004 by Gauthier Philippart and Jean-Luc Morelle, the designers of the first radio-synthesizers to combine high-yield synthesis and GMP.
They put together their expertise and their knowledge of the radiopharmaceutical industry and founded Trasis, an innovative and forward-looking company. Trasis has now a track record in developing instruments and methods recognized throughout the world.
At Trasis we are dedicated to helping the medical community access new radio-labeled therapeutic and diagnostic substances easily and faster. To this end, we design, manufacture, sell and support high-performance synthesizers, dose preparation equipment, their shielding, and accessories. We also develop customized synthetic methods and instruments. We can provide GMP Active Pharmaceutical Ingredients (API) and assist our customers with their regulatory affairs.
Our proven radiopharmaceutical expertise, coupled with our high-end instruments allow us to provide fully integrated solutions for effective tracer production and faster transition from drug development to marketing authorization.
Our equipment is used worldwide in nuclear medicine departments, research centers, radiopharmaceutical production facilities, and pharmaceutical companies.